Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
WALTHAM, Mass., Feb. 25, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- Canaccord Genuity 11th Annual Musculoskeletal Conference – Orlando, FL (March 1, 2016)
Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Tuesday, March 1, 2016, at 3:00 pm EST. The conference immediately precedes the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 36th Annual Health Care Conference – Boston, MA (March 7-9, 2016)
Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Monday, March 7, 2016, at 4:00 pm EST.
The live webcasts may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcasts will be available on Histogenics’ website for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
